Abstract
HIV protease inhibitors are antiretroviral drugs able to prevent production of infectious particles. It has been shown that these protease inhibitors are able to inhibit cancer-promoted angiogenesis in patients affected by Kaposi's sarcoma. A preliminary phase I study on dogs with stage III splenic hemangiosarcoma was designed in order to evaluate the efficacy and toxicity of the protease inhibitor Indinavir to delay the progression of this advanced neoplasm. The results suggest that Indinavir is potentially beneficial in dogs affected by microscopic residual disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Dog Diseases / drug therapy*
-
Dog Diseases / metabolism
-
Dogs
-
Fibroblast Growth Factor 2 / biosynthesis
-
HIV Protease Inhibitors / therapeutic use*
-
Hemangiosarcoma / drug therapy*
-
Hemangiosarcoma / metabolism
-
Hemangiosarcoma / veterinary
-
Indinavir / therapeutic use*
-
Splenic Neoplasms / drug therapy*
-
Splenic Neoplasms / metabolism
-
Splenic Neoplasms / veterinary
-
Vascular Endothelial Growth Factor A / biosynthesis
Substances
-
HIV Protease Inhibitors
-
Vascular Endothelial Growth Factor A
-
Fibroblast Growth Factor 2
-
Indinavir